menu
    • menu
    [{"orgOrder":0,"company":"American Regent","sponsor":"Provepharm Life Solutions","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Methylene Blue","moa":"Monoamine oxidase","graph1":"Hematology","graph2":"Approved FDF","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"American Regent \/ Provepharm Life Solutions","highestDevelopmentStatusID":"15","companyTruncated":"American Regent \/ Provepharm Life Solutions"},{"orgOrder":0,"company":"Nexus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Methylene Blue","moa":"Monoamine oxidase","graph1":"Hematology","graph2":"Approved FDF","graph3":"Nexus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nexus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nexus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ondine Biomedical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Methylene Blue","moa":"||Monoamine oxidase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ondine Biomedical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Solution","sponsorNew":"Ondine Biomedical \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Ondine Biomedical \/ Inapplicable"},{"orgOrder":0,"company":"Ondine Biomedical","sponsor":"Healthcare's Memorial Health University Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Methylene Blue","moa":"||Monoamine oxidase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Ondine Biomedical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Topical Solution","sponsorNew":"Ondine Biomedical \/ Healthcare's Memorial Health University Medical Center","highestDevelopmentStatusID":"10","companyTruncated":"Ondine Biomedical \/ Healthcare's Memorial Health University Medical Center"}]

    Find Clinical Drug Pipeline Developments & Deals for azul de metileno

    Menu

    azul de metileno

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ondine Biomedical

                            Canada arrow
                            Cophex
                            Not Confirmed

                            Ondine Biomedical

                            Canada arrow
                            Cophex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methylene Blue,Chlorhexidine Gluconate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ondine Recruits First Patient for US Phase 3 Trial

                            Details : Nasal antimicrobial photodisinfection therapy consisiting of NF-031 (methylthioninium chloride & chlorhexidine gluconate) is being evaluated for treatment of surgical site infections.

                            Product Name : NF-031

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 30, 2024

                            Lead Product(s) : Methylene Blue,Chlorhexidine Gluconate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Nexus Pharmaceuticals

                            U.S.A arrow
                            Cophex
                            Not Confirmed

                            Nexus Pharmaceuticals

                            U.S.A arrow
                            Cophex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methylene Blue

                            Therapeutic Area : Hematology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nexus Pharmaceuticals Receives FDA Approval for Methylene Blue Injection, USP

                            Details : The US FDA approved Methylene Blue Injection, USP (methylene blue). It is an oxidation-reduction agent that offers treatment of acquired methemoglobinemia.

                            Product Name : Methylene Blue Injection, USP

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 26, 2024

                            Lead Product(s) : Methylene Blue

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ondine Biomedical

                            Canada arrow
                            Cophex
                            Not Confirmed

                            Ondine Biomedical

                            Canada arrow
                            Cophex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methylene Blue,Chlorhexidine Gluconate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Healthcare's Memorial Health University Medical Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ondine Biomedical Completes Patient Recruitment for US Phase II Nasal Photodisinfection Trial

                            Details : Photodynamic Antimicrobial Chemotherapy (PACT) using methylene blue is a potential antimicrobial therapy that combines light and a photosensitizing drug, promoting a phototoxic effect on the treated cells increases membrane permeability in Candida albica...

                            Product Name : PACT

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 08, 2022

                            Lead Product(s) : Methylene Blue,Chlorhexidine Gluconate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Healthcare's Memorial Health University Medical Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            American Regent

                            U.S.A arrow
                            Cophex
                            Not Confirmed

                            American Regent

                            U.S.A arrow
                            Cophex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Methylene Blue

                            Therapeutic Area : Hematology

                            Study Phase : Approved FDF

                            Sponsor : Provepharm Life Solutions

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            American Regent Launches a New Vial Presentation

                            Details : ProvayBlue (methylene blue) is hypotonic and may be diluted before use in a solution of 50 mL 5% Dextrose Injection in order to avoid local pain, particularly in the pediatric population. Use the diluted solution immediately after preparation.

                            Product Name : ProvayBlue

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 30, 2022

                            Lead Product(s) : Methylene Blue

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved FDF

                            Sponsor : Provepharm Life Solutions

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth